TP53 and cancer: Nevertheless, these collectively suggest that RSK2Ser227 and the NTKD are potential therapeutic targets in many types of cancers, including MCL regardless of mutation status of TP53 which associates with adverse prognosis.15, 16, 17, 26, 27, 28, 29